Please login to the form below
Deal Watch table for April 2013
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers during April 2013.
For an indepth analysis of these deals, read 'Pharma deals during April 2013'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Conceptus/ Bayer | Acquisition | Birth control device | 1,100 |
| Actient Holdings/ Auxilium Pharmaceuticals | Acquisition | Urology specialty therapeutics company | 585 |
| Avalon/GSK | Funding | To fund up to 10 drug-discovery start-up companies over the next 3 years | 495 |
| Prolor Biotech/ Opkp Health | Acquisition | Longer-acting proprietary versions of approved therapeutic proteins | 480 |
| Isis Pharmaceuticals/ Roche | Collaboration | To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology | 392 |
| Ambrx/ Astellas Pharma | Collaboration | Oncology discovery and development of novel antibody drug conjugates | 300 |
| Alchemia/ AstraZeneca | Collaboration | VAST discovery platform – multiple targets | 240+ |
| TaslyDiyi Pharma/ Tasly Pharmaceuticals | Acquisition | Maker of chemical drugs | 240 |
| Bavarian Nordic/ US Government | Award | Smallpox vaccine research | 228 |
| Bind Therapeutics/ Pfizer | Collaboration | Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins | 210+ |
| Ra Pharma/ Merck & Co | Collaboration | Extreme Diversity™ platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas | 200 |
| Forma Therapeutics/ Celgene | Collaboration | Drug-discovery platform for compounds against protein homeostasis targets | 200 |
| Bind Therapeutics/ AstraZeneca | Collaboration | Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins, based on an AZ kinase inhibitor | 199 |
| Velcera/ Perrigo Company | Acquisition | Pet health products | 160 |
| Santaris Pharma/ BMS | Collaboration | Discover and develop RNA-targeted therapies based on the LNA Drug platform | 100 |
| China Animal Health Care/ Elanco (Lilly) | Part acquisition | Manufacturing, sale and distribution of animal drugs in China | 100 |
| Horizon Discovery/ AstraZeneca | Collaboration | Kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types | 75 |
| Achaogen/ Biomedical Advanced Research and Development Authority (BARDA) | Award | Phase 3 study - plazomicin to treat gram -ve bacterial infections due to Carbapenem-resistant Enterobacteriaceae | 60 |
| Pfizer/ Merck & Co* | Collaboration | Ertugliflozin as standalone and combination with Januvia and/or metformin for diabetes | 60 |
| Bracco Diagnostics/ Emergent BioSolutions | Asset purchase | Healthcare Protective Products Division | 26 |
Unless noted all transactions are for global rights
* Worldwide excluding Japan
Subscribe to our email news alerts
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
- Man vs microbe: the fight against antimicrobial resistance
- Dollo's law
No results were found
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
